Rockefeller Capital Management L.P. Boosts Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Rockefeller Capital Management L.P. lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 302,500 shares of the biotechnology company's stock after buying an additional 35,867 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.16% of BioMarin Pharmaceutical worth $19,883,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund increased its position in shares of BioMarin Pharmaceutical by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock worth $2,546,000 after purchasing an additional 164 shares in the last quarter. Fifth Third Bancorp boosted its holdings in BioMarin Pharmaceutical by 13.9% in the fourth quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock worth $89,000 after acquiring an additional 165 shares in the last quarter. TD Private Client Wealth LLC grew its stake in shares of BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares during the last quarter. First Hawaiian Bank increased its holdings in shares of BioMarin Pharmaceutical by 1.4% during the fourth quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock valued at $966,000 after acquiring an additional 200 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in shares of BioMarin Pharmaceutical by 64.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 233 shares during the last quarter. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Up 0.6 %

Shares of NASDAQ:BMRN traded up $0.35 during mid-day trading on Friday, reaching $59.17. 1,247,162 shares of the company were exchanged, compared to its average volume of 1,885,792. The firm has a market cap of $11.29 billion, a price-to-earnings ratio of 26.90, a P/E/G ratio of 0.61 and a beta of 0.30. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a 1 year low of $52.93 and a 1 year high of $94.85. The firm's 50-day simple moving average is $66.74 and its 200 day simple moving average is $66.27.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. Equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,344 shares of BioMarin Pharmaceutical stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the transaction, the chief accounting officer now owns 13,105 shares in the company, valued at approximately $896,119.90. This trade represents a 9.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have weighed in on BMRN shares. Wedbush restated an "outperform" rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $90.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Citigroup raised their price objective on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. UBS Group upped their target price on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Finally, Bank of America raised their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $94.00.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.